×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Prostate Cancer

Feature Video
Receiving a diagnosis of prostate cancer can be frightening and confusing. Understanding the details of your specific cancer and how they relate to your prognosis and treatment planning is an important first step toward shared decision-making between you and your physicians. In these CURE Connections programs you will learn the meaning of the PSA test, prostate cancer staging and grading, and how these factors are used to determine which treatment approach is right for you. Management of prostate cancer related symptoms, available treatments, and how to deal with side effects are also discussed. In addition, you will hear from patients and caregivers about their personal experiences with prostate cancer.
Jessica Skarzynski
Recent changes to the National Comprehensive Cancer Network (NCCN) guidelines around prostate cancer have updated the indications for genetic testing and have opened up a broader discussion on how it can be used to improve prostate cancer detection and treatment, according to Dr. James Mohler.
Marilyn Fenichel
Active surveillance has become the treatment of choice for low-risk prostate cancer, but new tools are needed to make it more precise.
Debu Tripathy, M.D.
In the medical community, we know that, at a population level, active surveillance is better for certain men with prostate cancer, so we believe the benefit weighs in their favor. We would like to offer men more certainty that surveillance can work for them and hope that, in the next few years, research will bring that to pass.
Jason Harris
Obese patients being treated for breast or prostate cancer showed higher levels of mental and physical distress than nonobese patients with these diseases, but the pattern did not hold true in those with colorectal cancer, according to a study.
 
Kristie L. Kahl
A recent study found no different in disease recurrence among men with prostate cancer when they were given radiation after surgery or not.
Kristie L. Kahl
Phase 3 trial findings showed that treatment with Lynparza delayed disease progression by about four months compared with newer hormonal agents in pre-treated patients with metastatic castration-resistant prostate cancer and faulty DNA repair genes.
Kristie L. Kahl and Gina Columbus
Morever, the next-generation androgen receptor improved overall survival, compared with placebo, in patients with nonmetastatic castration-resistant prostate cancer, according to updated findings of the phase 3 SPARTAN trial.
 
Kristie L. Kahl
Here is a list of the recent trial initiations that occurred within the cancer space in September.
 
Jessica Skarzynski
For Prostate Cancer Awareness Month, here’s a round-up of the latest news and updates in this disease space.
Kristie L. Kahl
Men with castration-sensitive prostate cancer now have an option for when treatment with androgen deprivation therapy alone is not enough.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×